Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Morelli

Showing results (11-20 of 362) with videos related to

Pageof 37
Sort By:
Neurotoxicity Research|April 28, 2004
Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's diseaseM Morelli, J Wardas
Behavioural Pharmacology|March 16, 2005
Caffeine and the dopaminergic systemO Cauli, M Morelli
Psychopharmacology|January 1, 1990
Stereospecific blockade of N-methyl-D-aspartate transmission by MK 801 prevents priming of SKF 38393-induced turningM Morelli, G Di Chiara
European Journal of Pharmacology|September 2, 1987
Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turningM Morelli, G Di Chiara
Brain Research|August 26, 1985
Non-dopaminergic mechanisms in the turning behavior evoked by intranigral opiatesM Morelli, G Di Chiara
Advances in Neurology|January 1, 1993
Dopamine-acetylcholine-glutamate interactions in the striatum. A working hypothesisG Di Chiara, M Morelli
European Journal of Pharmacology|November 5, 1985
Catalepsy induced by SCH 23390 in ratsM Morelli, G Di Chiara
European Journal of Pharmacology|July 17, 1990
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's diseaseM Morelli, G Di Chiara
Fertility and Sterility|October 10, 2002
Metformin and BMI?Elizabeth M Morelli, Richard V Grazi
Clinical Child and Family Psychology Review|November 29, 2021
A Systematic Review of the Validity, Reliability, and Clinical Utility of Developmental Trauma Disorder (DTD) Symptom CriteriaNicholas M Morelli, Miguel T Villodas
Pageof 37

Showing results (11-20 of 362) with videos related to

Sort By:
Pageof 37
Neurotoxicity Research|April 28, 2004
Adenosine A(2a) receptor antagonists: potential therapeutic and neuroprotective effects in Parkinson's diseaseM Morelli, J Wardas
Behavioural Pharmacology|March 16, 2005
Caffeine and the dopaminergic systemO Cauli, M Morelli
Psychopharmacology|January 1, 1990
Stereospecific blockade of N-methyl-D-aspartate transmission by MK 801 prevents priming of SKF 38393-induced turningM Morelli, G Di Chiara
European Journal of Pharmacology|September 2, 1987
Agonist-induced homologous and heterologous sensitization to D-1- and D-2-dependent contraversive turningM Morelli, G Di Chiara
Brain Research|August 26, 1985
Non-dopaminergic mechanisms in the turning behavior evoked by intranigral opiatesM Morelli, G Di Chiara
Advances in Neurology|January 1, 1993
Dopamine-acetylcholine-glutamate interactions in the striatum. A working hypothesisG Di Chiara, M Morelli
European Journal of Pharmacology|November 5, 1985
Catalepsy induced by SCH 23390 in ratsM Morelli, G Di Chiara
European Journal of Pharmacology|July 17, 1990
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's diseaseM Morelli, G Di Chiara
Fertility and Sterility|October 10, 2002
Metformin and BMI?Elizabeth M Morelli, Richard V Grazi
Clinical Child and Family Psychology Review|November 29, 2021
A Systematic Review of the Validity, Reliability, and Clinical Utility of Developmental Trauma Disorder (DTD) Symptom CriteriaNicholas M Morelli, Miguel T Villodas
Pageof 37